VENUS®
Enjoy Innovations

VRL/SEC/NSE 04.08.12

National Stock Exchange of India Ltd.
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Outcome of Board Meeting held on 04.08.2012

Dear Sir/Madam,

This is to inform you that the Board of Directors at its meeting held today , have approved Unaudited Financial Results (Provisional) for the quarter ended 30/06/2012 .

Kindly acknowledge the receipt.

Thanking you

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha Kodan
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL

UKAS QUALITY MANAGEMENT

UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 04 Aug. 2012 13:45 P 1

VENUS
Enjoy Innovations

VRL/SEC/NSE 04.08.12

National Stock Exchange of India Ltd.
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Unaudited Financial Results (Provisional) for the quarter ended 30.06.2012

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results (Provisional) for the quarter ended 30.06.12 along with Limited Review Report, which were taken on record by the Board of Directors at its meeting held on 04.08.12.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha Kodan
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

MOODY INTERNATIONAL
UKAS QUALITY MANAGEMENT
UKAS ENVIRONMENTAL MANAGEMENT

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 04 Aug. 2012 13:46 P 2

VENUS®
Enjoy Innovations

VENUS REMEDIES LIMITED
UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30TH JUNE, 2012

(Rs. In Millions)

S. No.	Particulars	Quarter Ended on			Year Ended on
	Part – I	30/06/2012 Unaudited	31/03/2012 Unaudited	30/06/2011 Unaudited	31/03/2012 Audited
1	Net Sales/ Income from operations				
	Gross Sales	1123.75	1137.15	990.75	4,023.91
	Less : Excise Duty	3.41	2.44	2.04	7.38
	(a) Net Sales	1120.34	1134.71	988.71	4,016.53
	(b) Other Operating Income	5.38	12.21	1.38	35.34
	Total Income from Opeartion (Net)	1,125.72	1,146.92	990.09	4,051.87
2	Expenses				
	(a) Consumption of raw materials	652.37	646.48	622.36	2,350.71
	(b) (Increase)/ Decrease in stock in trade	-29.75	0.21	-78.39	-90.33
	(c) Employee benefits expense	57.10	55.79	54.58	205.78
	(d) Depreciation & amortisation expense	77.69	61.31	60.72	240.67
	(e) Other expenses	148.80	161.78	110.31	524.69
	Total expense	906.21	925.57	769.58	3,231.52
3	Profit from opeartions beforo other income , finance costs and exceptional items (1-2)	219.51	221.35	220.51	820.35
4	Other income	1.26	2.01	0.41	3.80
5	Profit before finance costs and exceptional items (3+4)	220.77	223.36	220.92	824.15
6	Finance Costs	76.15	72.60	60.99	272.64
7	Profit after finance costs but before exceptional items (5-6)	144.62	150.76	159.93	551.51
8	Exceptional items	0.00	0	0	00.00
9	Profit from ordinary activities before tax (7+8)	144.62	150.76	159.93	551.51
10	Tax expense	4.17	-4.84	23.75	51.22
11	Profit from ordinary activities after tax (9-10)	140.45	155.60	136.18	500.29
12	Exceptional items (net of tax expense	00.00	0.00	0.00	0.00
13	Net profit for the period (11-12)	140.45	155.60	136.18	500.29
14	Paid up Equity Share Capital	97.42	97.42	91.29	97.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	3,003.48
16	E.P.S - Basic not annualised for the qtr	14.42	15.97	14.92	12.84
	- Annualised	57.67	63.88	59.67	51.35
	PART – II				
1	Public Shareholding				
	- Number of Shares	6388986	6388986	6376092	6388986
	- Percentage of Shareholding	65.58	65.58	69.84	65.58
2	Promoters and promoter group shareholding				
	a) Pledged as collateral security to bank				
	- Number of Shares	1930000	1930000	1930000	1930000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	57.56	57.56	70.10	57.56
	- Percentage of shares (as a % of the total share capital	19.81	19.81	21.14	19.81
	b) Non-Encumbered				
	- Number of Shares	1423002	1423002	823002	1423002
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	42.44	42.44	29.89	42.44
	- Percentage of shares (as a % of the total share capital	14.61	14.61	09.01	14.61

Particulars	3 months ended 30.06.12
(B) INVESTOR COMPLAINTS	NIL
Pending at the beginning of the quarter	2
Received during the quarter	2
Disposed of during the quarter	NIL
Remaining unresolved at the end of the quarter	

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

FROM :VENUS FAX NO. :0172 2565566 04 Aug. 2012 13:46 P 3

Notes:

1. The above Un-audited (Provisional) financial Results for the period ended 30.06.2012 were reviewed by the Audit Committee and taken on record at the board Meeting on August 4, 2012.

2. During the Quarter:

a) Company's research product CSE1034 wins US Patent, this novel antibiotic adjuvant entity (AAE) has been found effective against a wide range of drug resistant infections including the 'superbugs' like carbapenemase resistant Metallobetalactamses (MBL) strains

b) The Company has received its first patent for a novel antibiotic combination of carbapenem and aminoglycoside from South Africa.

c) The Company has established pre-clinical proof of concept for its Drug -Protein-Polymer-Conjugate (DPPC), an Innovative Solution for alleviating cancer and receptor diseases by a specific & selective targeting.

d) The Company has added another patent to its kitty for "Vancoplus®" from Australia

3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.

4. During the Quarter, two investor grievances were received and both are resolved. No other investor grievance was pending at the end of the quarter.

5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

(Pawan Chaudhary)
Chairman & Managing Director

Place : Panchkula
Date : 04.08.12

J. K. JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS
S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022
0172-270 4536-37 Fax : 0172-270 4537
E-mail : jkjcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of **Venus Remedies Limited** for the Quarter ended 30.06.2012. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,
(Chartered Accountants)

J. K. Jain

J. K. & ASSOCIATES CHARTERED ACCOUNTANTS FRN.004025N CHANDIGARH

(J.K.Jain)
Partner
M.No. 083140

Date : 03.08.2012
Place : Chandigarh

Certified to be true copy
For Venus Remedies Limited

(Company Secretary)

FROM :VENUS FAX NO. :0172 2565566 04 Aug. 2012 13:47 P 5